Indolent Non-Hodgkin lymphoma
Showing 1 - 25 of >10,000
Patterns in People With Indolent Non-Hodgkin Lymphoma,Type of
Active, not recruiting
- Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
- Copanlisib (BAY80-6946)
-
Multiple Locations, TaiwanMany Locations
Jan 31, 2023
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)
Completed
- Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
- Imprime PGG
- Rituximab
-
Boston, MassachusettsDana Farber Cancer Institute
Sep 20, 2022
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,
Completed
- Grade 3a Follicular Lymphoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023
Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,
Withdrawn
- Recurrent Follicular Lymphoma
- +8 more
- (no location specified)
Jun 2, 2022
Waldenstrom Macroglobulinemia Trial in United States (Umbralisib)
Completed
- Waldenstrom Macroglobulinemia
-
Washington, District of Columbia
- +3 more
Oct 19, 2022
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)
Not yet recruiting
- Follicular Lymphoma
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Mar 13, 2023
Non Hodgkin's Lymphoma Trial in Sacramento, Santa Rosa (Rituximab, Lenalidomide)
Active, not recruiting
- Non Hodgkin's Lymphoma
-
Sacramento, California
- +1 more
Nov 15, 2021
Follicular Lymphoma, Marginal Zone Lymphoma Trial in Italy, Spain, United States (EO2463, lenalidomide, rituximab)
Recruiting
- Follicular Lymphoma
- Marginal Zone Lymphoma
- EO2463
- +2 more
-
Boston, Massachusetts
- +9 more
Jul 26, 2022
Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma Trial in Duarte, Boston, Portland (Copanlisib, Nivolumab)
Recruiting
- Chronic Lymphocytic Leukemia
- +6 more
- Copanlisib
- Nivolumab
-
Duarte, California
- +2 more
Mar 9, 2022
R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial (CNTY-101, IL-2,
Recruiting
- R/R CD19-Positive B-Cell Malignancies
- +2 more
- CNTY-101
- +2 more
-
Detroit, Michigan
- +1 more
Dec 21, 2022
CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)
Terminated
- CD20-positive Non-Hodgkin Lymphoma
- Rituximab + MG4101
-
Seoul, Korea, Republic ofSeoul National University Hospital
Oct 24, 2022
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,
Active, not recruiting
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +9 more
- BTK inhibitor PCI-32765
- +5 more
-
Columbus, OhioOhio State University Medical Center
Jun 27, 2022
Indolent Non-hodgkin Lymphoma Trial in Shanghai (IBI376)
Active, not recruiting
- Indolent Non-hodgkin Lymphoma
-
Shanghai, ChinaRuijin hospital, school of medicine, Shanghai jiao tong universi
Oct 3, 2022
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Rochester (procedure, biological,
Active, not recruiting
- Aggressive Non-Hodgkin Lymphoma
- +9 more
- Cryosurgery
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 9, 2022
Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2
Active, not recruiting
- Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
- +22 more
- External Beam Radiation Therapy
- Orbital Radiation
-
Houston, TexasM D Anderson Cancer Center
Dec 9, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Venetoclax
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +15 more
- Anti-CD19/CD20/CD22 CAR T-Cells
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 4, 2022
Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma Trial in United States (dietary supplement, biological,
Active, not recruiting
- Follicular Lymphoma
- +3 more
- Vitamin D
- +2 more
-
Miami, Florida
- +6 more
Mar 6, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +23 more
- Lenalidomide
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 23, 2022
DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,
Not yet recruiting
- DLBCL - Diffuse Large B Cell Lymphoma
- +6 more
- Bridging radiation therapy
- +2 more
- (no location specified)
Jan 4, 2023
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Atlanta (drug, biological,
Recruiting
- Grade 1 Follicular Lymphoma
- +7 more
- Acalabrutinib
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Dec 7, 2021
Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker
Active, not recruiting
- Follicular Lymphoma
- +2 more
- Laboratory Biomarker Analysis
- Pembrolizumab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 6, 2022
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent
Completed
- Ann Arbor Stage III Grade 1 Follicular Lymphoma
- +9 more
- Lenalidomide
- Rituximab
-
Houston, TexasM D Anderson Cancer Center
Sep 28, 2021
Severe COVID-19 Infection in CLL or B-NHL Who Received
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- (no location specified)
Apr 6, 2023